Last week, the U.S. Food and Drug Administration (FDA) decided to permanently allow mifepristone to be sent through the mail.
Reuters reported that the FDA originally allowed mifepristone, also known as the “morning after pill,” to be sent through the mail without a doctor’s visit at the start of the COVID-19 pandemic.
The drug is approved for use up to 10 weeks of pregnancy and is also sometimes prescribed to treat women who are having miscarriages. It was approved in 2000.
“The FDA’s decision will come as a tremendous relief for countless abortion and miscarriage patients,” Georgeanne Usova, senior legislative counsel at the ACLU, told the news service
The ACLU of Illinois welcomed the news.
“Overall this is a good development, and an important step against the effort across the country to force people to carry pregnancy to term,” said Ed Yonha, communications director for ACLU of Illinois. “It is clear that this will help people in underserved areas. It is not clear how the issue of mailing across state lines will be resolved.”
The action comes as abortion access is a major battlefront across the country. Many states have passed restrictive laws on abortion while other states, like Illinois, have worked to ease access.